Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Winlevi is authorized in EU for the treatment of acne vulgaris
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Maria Soler Nunez appointed as Chief Quality Officer
Subscribe To Our Newsletter & Stay Updated
